Influenza Reagent
Influenza Anti N9 Neuraminidase Serum SH592
NIBSC code: 13/166
Instructions for use

(Version 1.0, Dated 14/08/2013)

1. INTENDED USE
Influenza antiserum reagent 13/166 is prepared in sheep for neuraminidase
identity tests.

2. CAUTION
This preparation is not for administration to humans or animals in
the human food chain.

The material is not of human or bovine origin. As with all materials of
biological origin, this preparation should be regarded as potentially
hazardous to health. It should be used and discarded according to your
own laboratory's safety procedures. Such safety procedures should
include the wearing of protective gloves and avoiding the generation of
aerosols. Care should be exercised in opening ampoules or vials, to
avoid cuts.

3. UNITAGE
No unitage is assigned to this material.

4. CONTENTS
Country of origin of biological material: United Kingdom.
The antiserum was prepared in a SHEEP (SH592) to A/Anhui/1/2013
(H7N9) inactivated virus. One dose of approximately 50 micrograms
of virus protein with Freund's complete adjuvant (FCA) was given
intramuscularly, a further dose of approximately 10 micrograms with
Freund's incomplete adjuvant (FIA), was given two weeks later. This was
followed by a further four 10microgram doses, with FIA, at weekly
intervals.

Eight weeks after the initial immunization, serum was collected, sodium
azide was added (0.05% w/v). The serum was treated using an APHIS
approved method for inactivation of FMD virus, see attached certificate.
The serum was filled into vials in 1ml volumes. The mean weight of 15
vials test weighed was 1.12g with a coefficient of variation of 0.88%.

5. STORAGE
+2-8°C
Please note: because of the inherent stability of lyophilized
material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
Vials have a ‘flip-up’ circular cap. Either on the cap or the collar of the
vial, there is an indication of the point at which to lever off the cap. This
exposes an area of the stopper through which reconstitution and
withdrawal of the preparation can be made using a hypodermic needle
and syringe. If use of a pipette is preferred, then fully remove the metal
collar using, for example, forceps, taking care to avoid cuts by wearing
appropriate gloves. Remove the stopper for access. Care should be
taken to prevent loss of the contents.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the
material
Reagent 13/166 should be used in tests of neuraminidase identity, such as the
neuraminidase inhibition (NI) test of Aymard-Henry M, Coleman MT,
Dowdle WR, Laver WC, Schild GC and Webster FG. Bull WHO, 1973, 48,
199-202. Although Reagent 13/166 does not have a unitage, in NI tests
titles are usually as indicated in the Appendix.

8. STABILITY
It is the policy of WHO not to assign an expiry date to their international
reference materials. They remain valid with the assigned potency and
status until withdrawn or amended.

Reference materials are held at NIBSC within assured, temperature-
controlled storage facilities. Reference Materials should be stored on
receipt as indicated on the label. Please also see attached storage
information sheet. Once reconstituted, diluted or aliquoted, users should
determine the stability of the material according to their own method of
preparation, storage and use.

NIBSC follows the policy of WHO with respect to its reference materials.
Users who have data supporting any deterioration in the characteristics
of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES
Amard-Henry, M., Coleman, M.T., Dowdle, W.R., Laver, W.G., Schild,
G.C and Webster, R.G. 1973. Influenza virus neuraminidase inhibition

10. ACKNOWLEDGEMENTS
N/A

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use
of the material provided or other aspects of our service. Please send
any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is
referred to, it is important that the preparation's title, its status, the
NIBSC code number, and the name and address of NIBSC are cited
and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC)
No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Liquid</td>
</tr>
<tr>
<td>Stable: Yes</td>
</tr>
<tr>
<td>Hygroscopic: No</td>
</tr>
<tr>
<td>Flammable: No</td>
</tr>
</tbody>
</table>
Other (specify): Contains Sheep Serum and Sodium Azide (0.05% w/v)

### Toxicological properties

- Effects of inhalation: No adverse effects have been reported
- Effects of ingestion: No adverse effects have been reported
- Effects of skin absorption: No adverse effects have been reported

### Suggested First Aid

**Inhalation:** Seek medical advice

**Ingestion:** Seek medical advice

- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash thoroughly with water.

### Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

### 16. INFORMATION FOR CUSTOMS USE ONLY

**Country of origin for customs purposes**: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

**Net weight**: 1g

**Toxicity Statement**: Non-Toxic

**Veterinary certificate or other statement if applicable**

**Attached**: No, SH592 Vet Certificate, FMD Inactivation Certificate and Appendix, including storage Information sheet.
VETERINARY CERTIFICATE OF ANIMAL HEALTH

This is to certify that I have examined a Sheep with ear tag number: UK 028 8289 6217 [Virology no. SH592], which has been used in the production of blood antiserum between 7th May 2013 and 3rd July 2013. Both the ear tag number and the animals’ record show that it is of UK origin.

This animal was a breeding Ewe which became surplus to requirements. In my opinion at the time of clinical examination, the ewe was in good health and showed no clinical signs of infectious disease.

[Signature]

Arturo Fernandez DVM MRCVS
Named Veterinary Surgeon

Arturo Fernandez DVM MRCVS
Named Veterinary Surgeon (NVS) Group
The Royal Veterinary College, Royal College Street, London NW1 0TU
Mobile: 07733 103881, E-mail:
Foot and Mouth Disease Virus Inactivation Certificate

This is to certify that serum collected from Sheep no. UK 0288 289 6217 [Virology no.SH592 ] has been treated by an APHIS approved method for inactivation of Foot and Mouth Disease Virus. The treatment method used was maintenance of pH5.5 or lower for a minimum of 40 minutes.

[Signature]

Dr Philip Minor
Deputy Director
National Institute for Biological Standards and Control
Appendix

Neuraminidase inhibition titres of 13/166

<table>
<thead>
<tr>
<th>Antigen</th>
<th>NI Titre</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Anhui/1/2013 (H7N9)</td>
<td>6469</td>
</tr>
<tr>
<td>NIBRG-270 (H7N1) [A/Anhui/1/2013 x (A/PR/8/34)]</td>
<td>11</td>
</tr>
<tr>
<td>NYMC X157 (H3N2) [A/New York/55/2004 x (A/PR/8/34)]</td>
<td>13</td>
</tr>
</tbody>
</table>

NB This data is presented in order to provide an indication of the likely titre of this reagent in a *standard enzyme inhibition assay, on the understanding that individual test results will vary.

Please also note that in this test, 0.5 log$_{10}$ dilutions to 1:320000 of the serum were used with A/Anhui/1/2013 (H7N9) virus to determine the endpoint. *Standard 0.5 log$_{10}$ dilutions of 1:10 to 1:320 of the serum were sufficient with the other two viruses.

STORAGE OF REAGENT 13/166

NIBSC has prepared a number of reagents for single radial diffusion assay of influenza subtypes of pandemic potential.

Since it is not known when these reagents may be required, it is desirable that they have an indefinite shelf life and they are stored at NIBSC in colder conditions than reagents prepared for the assay of epidemic strains. Therefore the recommended storage temperature marked on the label for reagent 13/166 is -20°C.

However it is assumed that a customer ordering this reagent, will use it within a short period similar to that for a conventional reagent. Consequently, this reagent is not normally shipped frozen and the recommended storage temperature is +4°C.